Executive Search

Chief Medical Officer SynaptixBio is a rare disease biotech pioneering ground-breaking development for treatment of severe leukodystrophies. The company’s aim is to treat the genetic central nervous system disease TUBB4A-related leukodystrophy. First identified in 2015, TUBB4A-related leukodystrophy is caused by a mutation in the TUBB4A gene. It disrupts the growth or maintenance of the myelin sheath that insulates sections of the axon which results in retardation or stopping of nerve impulses in certain areas of the brain. Onset is typically recognised in toddlers with developmental delays and deterioration of motor function (gait dysfunction and difficulties with sitting, speech and swallowing). [...]

Chief Business Officer CHARM Therapeutics is a protein-ligand intelligence company turning advanced protein-ligand prediction into impactful medicines. CHARM’s advanced protein-ligand prediction platform, DragonFold, provides unique 3D insights into the dynamic structure of the protein-ligand binding interactions, with the potential for profound impacts on the design of novel molecules and delivery of new medicines. The Company’s initial focus is novel small molecules to treat cancer, but the technology is potentially applicable to many other therapeutic areas. CHARM is based in Cambridge and London and has raised $70 million to date, supported by high quality international investors including OrbiMed, F-Prime Capital, General [...]

SVP, Chemistry Founded by Advent Life Sciences, Amphista is a spin-out of TPD expert Professor Alessio Ciulli’s laboratories at the University of Dundee. The Company has raised over $60M to date and is funded by leading life science investors including Forbion, Gilde Healthcare, Novartis Venture Fund, Advent Life Sciences, Eli Lilly & Company and The Dementia Discovery Fund. Amphista is a leader in next generation targeted protein degradation (TPD) approaches and is currently applying its proprietary degrader platform to advance new approaches in TPD. The Company aims to address the challenges faced by earlier stage TPD research and transform the [...]

Chief Business Officer Head of LifeArc Ventures LifeArc is a leading independent medical research charity that rebranded since its formation as the MRC-T over 25 years ago. LifeArc’s expertise has helped bring a number of new innovations to market including major commercialised antibody treatments such as Keytruda® (pembrolizumab). The success of Keytruda® has resulted in the receipt of nearly £1billion for monetising a portion of its royalty rights, funds which LifeArc have sought to effectively deploy to increase the impact that they deliver. As LifeArc undergoes transformative change, Melanie Lee, CEO, sought to appoint several experienced executives from the life [...]

Chief Executive Officer Chief Commercial Officer Congenica is a digital health company enabling genomic medicine with the world’s leading clinical decision support platform for accelerated genomic data interpretation. Congenica are committed to integrating clinical genomics into healthcare. Built on a foundation of clinical genomics expertise, they develop software products and services that make the use of complex genomic data routine, accessible and ubiquitous. This innovative venture-capital backed growth stage business engaged Stuart Penney and Tom Bradley to build-out their executive team to scale the business as it commercialised internationally. As a result of an extensive global search exercise, both David [...]

Chief Scientific Officer Chief Medical Officer Zelluna Immunotherapy AS is a privately owned Norwegian biopharmaceutical company founded in 2016 focused on the development of TCR based immunotherapies targeting a broad range of solid cancers with a high unmet medical need. In November 2017 Zelluna announced the appointment of Miguel Forte as Chief Executive Officer.  One of Miguel’s key objectives is to lead Zelluna through its next stage of development by driving clinical translation of the TCR pipeline, developing new international scientific and commercial partnerships and forging relationships with the international investor communities. To assist Miguel in driving the business forward he [...]

Chief Medical Officer Chief Development Officer SVP Regulatory Affairs VP Clinical Operations NMD Pharma is a promising Danish biotechnology company dedicated to the development of a paradigm, innovative and life-changing treatment for patients with reduced muscle function due to compromised neuromuscular transmission as experienced in Myasthenia Gravis and other rare neuromuscular disorders. Following an impressive Series A funding round, backed by major venture capital players, the NMD Pharma Founders and Board engaged Tom Bradley and Stuart Penney to undertake two key searches for a Chief Medical Officer and Chief Development Officer to compliment the advancement of NMD Pharma key programmes [...]